Anthropic announced on Wednesday that its artificial intelligence model, Claude, had independently identified a new enzyme system within bacterial DNA, potentially marking the emergence of a novel gene-editing mechanism akin to CRISPR. The discovery was made at the prompting of researchers at the company’s newly established biology research laboratory in San Francisco.
The tech firm stated that the newly identified system exhibited traits found in only a small number of other “programmable” biological structures and displayed patterns similar to CRISPR, a genome-editing tool naturally occurring in bacteria. CRISPR technology has already been credited with significant advances in treating conditions such as sickle cell disease and cancer.
Although Anthropic has not yet determined the specific function of the system, CEO Dario Amodei suggested the “molecular machine” could represent a new method for editing genes. Amodei, who has previously predicted that AI could help cure most diseases within five to ten years, noted that the AI spent 21 hours searching a large database of DNA sequences to make the finding. He described AI as being at the “very beginning” of its capacity to drive medical breakthroughs.
Stanley Qi, an associate professor of bioengineering at Stanford University, called the reported discovery “incredibly exciting.” He highlighted the system’s ability to recognize complex biological patterns that were previously difficult to detect. “Nature contains an enormous diversity of molecular systems we barely understand,” Qi told Al Jazeera, adding that AI could significantly expand the speed and effectiveness of exploring these patterns.
However, not all experts shared the enthusiasm. Kevin Blake, a microbiologist at Washington University School of Medicine, expressed skepticism regarding the scientific significance of the announcement. He cautioned that while the identified array is “CRISPR-like,” this does not necessarily mean Anthropic has discovered a Nobel Prize-winning gene-editing technology.
“There’s nothing to indicate this is a rival to CRISPR-the-technology, or could be developed into any kind of therapeutic or practical application,” Blake said, noting that countless CRISPR-like sequences remain to be cataloged due to the millions of unstudied bacterial species.
The original CRISPR gene-editing technology was pioneered by Emmanuelle Charpentier and Jennifer Doudna, who were awarded the 2020 Nobel Prize in Chemistry for their work. Last year, the Children’s Hospital of Philadelphia reported a historic medical breakthrough, using customised CRISPR therapy to treat an infant born with carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disease.
It’s wild to think a language model is now helping us decode the fundamental machinery of life itself.
Stanford’s Qi seems genuinely thrilled, but Blake’s skepticism is fair. The gap between discovery and therapy is huge.
Keep your expectations in check. ‘Similar’ doesn’t mean ‘useful’ yet. We need functional validation before celebrating.
Really? A CRISPR-like enzyme identified in 21 hours. I find that timeline hard to believe without more data.
This is absolutely incredible! AI accelerating biological discovery changes everything for medical research.